TrialSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial.

Ahmad AlEid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.